Recently, Hunan Huateng Pharmaceutical Co., Ltd.(hereafter called Huateng Pharma) completed a series B financing of 117 million yuan. This round of financing was led by CITIC Securities, followed by Hunan Xingxiang Group, Shenzhen Hongfu No. 7, and Zhou Qilin, an academician of the Chinese Academy of Sciences.
Huateng Pharmac raised 50 million yuan in the series A round of funding led by Tianshili Capital's Boyi Fund and followed by Zhuhai Danchi Equity Investment Fund, and Hunan Dingteng Juzhi Investment Partnership.
On November 16, the 3rd Sustained Release Drug R&D International Summit and 2019 APIs Industrial Park (Changsha) Investment Cooperation Forum ended successfully in Changsha. The forum was hosted by the People's Government of Wangcheng District of Changsha City and the Promotion Office of Biomedical Industry Chain of Changsha City, and undertaken by Hunan Huateng Pharmaceutical Co., Ltd..
We are honored to invite you to attend the 3rd Sustained-Release Drug R&D International Summit to be held at Preess Resort & Hotel, Wangcheng, Changsha, Hunan, China, on November 14-16, 2019, which is organized by the People's Government of Wangcheng District, Changsha.
This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng)， as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter.